CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials

CSL Behring, a business unit of CSL, has been providing the Alpha-1 community with ZEMAIRA for 20 years, and are proud to continue to provide this safe and effective treatment option in additional vial sizes, which will serve to streamline the preparation process for ZEMAIRA, 4- and 5-gram vial sizes for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] are now available.

Lowering the number of vials certain patients need also positively contributes to CSL’s efforts to reduce waste in the supply chain and end-to-end production, which is an area of focus of the Environmental Pillar of CSL’s Sustainability Strategy.

Read more here: https://a1f.org/47BoMwo

Leave a Reply

Your email address will not be published. Required fields are marked *